“With the successful launch of Hydra in Hungary, SMT has further expanded it global TAVI program. We are thrilled with the positive feedback received and it inspires us to keep on innovating and creating a positive impact on patient healthcare,” said Gaurav Goel, President of SMT’s Hydra business.
With Hydra TAVI now available in 20+ countries, SMT’s global expansion strategy reflects its commitment to making high-quality cardiovascular solutions accessible worldwide. This availability emphasizes SMT’s mission to enhance patient outcomes by providing advanced, minimally invasive options for cardiac care globally.
“Hydra’s precision in implantation is essential to patient safety and treatment efficacy,” commented Dr. Zoltán Ruzsa, MD, PhD. “Our initial experience with Hydra has been very promising, supporting our goal to deliver advanced, effective care.”
Dr. Tamás Szücsborus Tamás added, “Hydra TAVI aligns perfectly with our objectives to provide patients with innovative and accessible solutions for aortic valve disease.”